Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg for idiopathic cardiomyopathy with myocardial parvovirus B19 persistence
NL-OMON33416Phase 3Active, not recruiting
- Sponsor
- Sanquin
- Start
- Oct 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-ischemic cardiomyopathy (NICM) and erythema infectiosum comparing Nanogam plus conventional heart failure therapy with Placebo plus conventional heart failure therapy (2 arms). Started Oct 2009; status: active, not recruiting.
02
Drugs
Nanogam
03
Conditions
non-ischemic cardiomyopathy (NICM)erythema infectiosum
Beyond the preview
Go deeper on NL-OMON33416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33416.